4D Molecular Therapeutics (NASDAQ:FDMT) Research Coverage Started at Chardan Capital

Chardan Capital assumed coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research note published on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $30.00 target price on the stock. Other analysts have also issued research reports about the company. 92 Resources reiterated a reiterates rating on […]

Related Keywords

United States ,America ,Jacob Chacko ,D Molecular Therapeutics Inc ,Arrowmark Colorado Holdings ,Geode Capital Management ,Chardan Capital ,Molecular Therapeutics ,Free Report ,Moderate Buy ,Global Investors Lp Viking ,Director Jacob Chacko ,Street Corp ,Capital Management ,Mark Colorado Holdings ,Sigma Advisers ,Two Sigma Investments ,Sigma Investments ,Molecular Therapeutics Daily ,